Biote Corp. Reports Q2 2025 Revenue of $48.9 Million, Net Income Turnaround

Biote Corp. reported its financial results for the second quarter of 2025, revealing a total revenue of $48.9 million, a slight decrease of 0.6% from $49.2 million in the same period last year. The company's product revenue was $47.7 million, down from $48.1 million, while service revenue increased to $1.2 million from $1.1 million. The net income for the quarter was $3.9 million, a significant turnaround from a net loss of $10.4 million in the prior year, reflecting improved operational efficiency and cost management.

In comparison to the previous fiscal period, Biote's financial performance showed notable improvements. The company reported an income from operations of $10.8 million, up from $6.2 million a year earlier. This increase was attributed to a reduction in the cost of revenue, which fell to $13.9 million from $15.4 million, primarily due to cost savings from the integration of Asteria Health, a 503B manufacturer of compounded bioidentical hormones acquired in March 2024. Selling, general, and administrative expenses also decreased to $24.2 million from $27.6 million, driven by lower employee-related costs and reduced consulting expenses.

Operationally, Biote has focused on expanding its network of certified practitioners and enhancing its product offerings. The company reported a rise in revenue from Biote-branded dietary supplements, which increased by $2.5 million, attributed to a shift in sales to its e-commerce platform on Amazon. The total number of Biote-certified practitioners remained stable, but the company faced challenges with clinic attrition and lower procedure volumes, which impacted overall revenue from pellet procedures.

Looking ahead, Biote's management expressed optimism about future growth, emphasizing their commitment to increasing the number of certified practitioners and expanding their product lines. The company has also implemented a restructuring plan aimed at improving financial performance, which included a workforce reduction of approximately 15 roles. Despite the challenges posed by market conditions and competition, Biote remains focused on leveraging its integrated business model and enhancing operational efficiencies to drive long-term growth. The company ended the quarter with cash and cash equivalents of $19.6 million, down from $39.3 million at the end of 2024, but maintains access to $50 million under its revolving credit facility.